Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MT-2766 in Japanese Adults
NCT05065619Phase 2Terminated
- Sponsor
- Medicago Inc.
- Start
- Oct 2021
- Primary completion
- Mar 2022
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of MT-2766 in coronavirus disease 2019 (COVID-19), sponsored by Medicago Inc.. Started Oct 2021; status: terminated.
02
Drugs
MT-2766
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05065619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065619.